High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867090/
https://ncbi.nlm.nih.gov/pubmed/29392887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13551
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados